Home

Applications

APPLICATIONS OVERVIEW
DRUG DISCOVERY
ADME-Tox
Biochemical Assays
Cell-based Assays
HTS and Secondary Screening
Microsampling
Protein Crystallography
RNAi
Sample Management
CANCER RESEARCH
Personalized Medicine
Functional Screening / DSRT
RNAi
Sequencing
Single-cell Genomics
GENOMIC RESEARCH
Gene Expression
Genotyping
Microbiome
qPCR
Sequencing
Single-cell Genomics
Synthetic Biology

Products

LIQUID HANDLING
LIQUID HANDLERS OVERVIEW
Echo® 525 Liquid Handler
Echo® 555 Liquid Handler
Echo® 550 Liquid Handler
Echo® 520 Liquid Handler
AUTOMATION
AUTOMATION OVERVIEW
Access™ Laboratory Workstation
Tempo™ Automation Control Software
SOFTWARE APPLICATIONS
SOFTWARE OVERVIEW
Echo® Array Maker
Echo® Cherry Pick
Echo® Combination Screen
Echo® Compliance Manager
Echo® Dose-Response
Echo® Plate Audit
Echo® Plate Reformat
CONSUMABLES
CONSUMABLES OVERVIEW
Echo® Qualified Microplates
Labcyte® Assay Microplates
MicroClime® Environmental Lid
Echo® Qualified Reservoir

Technology

Echo® Acoustic Liquid Handling
Dynamic Fluid Analysis™
Acoustic Mass Spectrometry
Direct Dilution

News / Events

Labcyte BLOG
Upcoming Events
Press Releases
Labcyte in the News
Labcyte Community

Resources

JALA Special Issue
Publications
Articles and Other Media
Application Notes
Posters
Webinars
Videos
Customer Profiles
Core Labs

Support

Brochures
Web Documentation*
User Guides*
Quick Start Guides*
Specification Sheets
Site Prep Guides
Service and Maintenance
Request Information

Company

About Us
Echo® Acoustic Technology
Leadership Team
Meet Labcyte
Careers
Contact and Location
Privacy Policy

Labcyte BLOG

EDITORIAL: We Can Save More Cancer Patients Right Now
FRIDAY, SEPTEMBER 16, 2016
linkedin twitter facebook |  46Shares

In a commentary just published in Drug Discovery & Development magazine, Labcyte CEO Mark Fischer-Colbrie discusses the opportunity to save more cancer patients through individualized medicine.


In the article, Fischer-Colbrie talks about pioneering work using cells from each patient to screen for the treatment that performs best against that particular cancer. These cell-based assays represent the real implementation of custom-tailored medicine that we’ve dreamed about for so many years, and they’re already being used to help patients today.


Fischer-Colbrie cites work from scientists at the Institute of Molecular Medicine in Finland (FIMM), where cell-based assays are used together with analyses of the patient and cancer genomes to understand why a drug (or drug combination) has a specific effect. It’s a revolutionary approach that incorporates a much-needed feedback loop to help improve treatment for all cancer patients. “In studies, this screening method has identified drugs that allowed patients to go into remission — including long-term patients who had already undergone many rounds of chemotherapy without clinical benefit,” Fischer-Colbrie writes, noting that it’s humbling to see that Labcyte tools are helping to make this possible.


The article also acknowledges that drug repurposing regulations and physician education will have to be addressed in order to maximize the value that these results might have in mainstream medicine.


“Millions of cancer patients are counting on us to bring advances like this to the clinic,” Fischer-Colbrie writes. “When we see such promise for saving lives, we must do everything we can to accelerate its development and expand its use.”